Delving into the Latest Updates on AbbVie Biotherapeutics, Inc. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

Small molecule drug

Monoclonal antibody

Diagnostic radiopharmaceuticals

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Hemic and Lymphatic Diseases	4
Immune System Diseases	3
Infectious Diseases	2
Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3
Monoclonal antibody	2
Antibody	1
Diagnostic radiopharmaceuticals	1
Trispecific antibody	1

Top 5 Target	Count

LILRB1 x LILRB2 x LILRB3	1
Bcl-2 x MALT1	1
TMEM175(transmembrane protein 175)	1
GITR x PD-1	1
LILRB4(Leukocyte immunoglobulin-like receptor subfamily B member 4)	1

Immunotoxicology/immunosafety science is rapidly evolving, with novel modalities and immuno-oncology among the primary drivers of new tools and technologies. The Immunosafety Working Group of IQ/DruSafe sought to better understand some of the key challenges in immunosafety evaluation, gaps in the science, and current limitations in methods and data interpretation. A survey was developed to provide a baseline understanding of the needs and challenges faced in immunosafety assessments, the tools currently being applied across the industry, and the impact of feedback received from regulatory agencies. This survey also focused on current practices and challenges in conducting the T-cell-dependent antibody response (TDAR) and the cytokine release assay (CRA). Respondents indicated that ICH S8 guidance was insufficient for the current needs of the industry portfolio of immunomodulators and novel modalities and should be updated. Other challenges/gaps identified included translation of nonclinical immunosafety assessments to the clinic, and lack of relevant nonclinical species and models in some cases. Key areas of emerging science that will add future value to immunotoxicity assessments include development of additional in vitro and microphysiological system models, as well as application of humanized mouse models. Efforts are ongoing in individual companies and consortia to address some of these gaps and emerging science.

01 Apr 2024·Cancer Chemotherapy and Pharmacology

Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study

Article

Author: Menon, Rajeev M ; Doi, Toshihiko ; Boehm, Nils ; de Jonge, Maja ; Biesdorf, Carla ; Siddani, Satya R ; Hoffman, David ; Rasco, Drew ; Medeiros, Bruno C ; Polepally, Akshanth R ; Guan, Xiaowen

PURPOSEEftozanermin alfa is a second-generation tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor agonist that enhances death receptor 4/5 clustering on tumor cells to induce apoptosis. We report the pharmacokinetics and immunogenicity of eftozanermin alfa administered intravenously to 153 adults with previously-treated solid tumors or hematologic malignancies from the first-in-human, open-label, dose-escalation and dose-optimization study.METHODSDose escalation evaluated eftozanermin alfa monotherapy 2.5-15 mg/kg on Day 1 or Days 1/8 of a 21-day cycle. Dose optimization evaluated eftozanermin alfa monotherapy or combination therapy with either oral venetoclax 400-800 mg daily (eftozanermin alfa 1.25-7.5 mg/kg Days 1/8/15 of a 21-day cycle) or chemotherapy (eftozanermin alfa 3.75 or 7.5 mg/kg Days 1/8/15/22 of a 28-day cycle and FOLFIRI regimen [leucovorin, 5-fluorouracil, and irinotecan] with/without bevacizumab on Days 1/15 of a 28-day cycle).RESULTSSystemic exposures (maximum observed concentration [C_max] and area under the concentration-time curve [AUC]) of eftozanermin alfa were approximately dose-proportional across the entire dose escalation range with minimal to no accumulation in Cycle 3 versus Cycle 1 exposures. Comparable exposures and harmonic mean half-lives (35.1 h [solid tumors], 31.3 h [hematologic malignancies]) were observed between malignancy types. Exposures (dose-normalized C_max and AUC) in Japanese subjects were similar to non-Japanese subjects. Furthermore, eftozanermin alfa/venetoclax combination therapy did not have an impact on the exposures of either agent. Treatment-emergent anti-drug antibodies were observed in 9.4% (13/138) of subjects.CONCLUSIONSThe study results, including a pharmacokinetic profile consistent with weekly dosing and low incidence of immunogenicity, support further investigation of eftozanermin alfa.TRIAL REGISTRATION IDNCT03082209.

01 Feb 2024·Current Protocols

Evaluation of Sort Recovery via Rmax

Article

Author: Perez-Gonzalez, Alexis ; Gardner, Rui ; Lopes, Telma ; Martinez, Lola ; Riddell, Andy ; Bispo, Claudia

AbstractCell sorting performance can be evaluated in regard to the purity and recovery of the sorted fractions. The purity provides checks on sample quality, acquisition settings, gating strategy, and the sort decisions made by the instrument, but alone it is not sufficient to evaluate sorting performance. Recovery, defined here as the number of target particles sorted relative to the number of original target particles to be sorted, is a key metric of sort fitness and performance but is often neglected due to difficulties in its measurement. Both purity and recovery require re‐sampling of the sorted fraction, but unlike determining purity, calculating recovery calls for the absolute counting of particles in the sorted fraction that comes with large errors, and may not be feasible for rare populations or precious samples.Here, we describe a recently developed metric and method for calculating sort recovery called Rmax, representing the maximum expected recovery for a particular set of instrument settings. Rmax calculation avoids re‐sampling of the total sorted fraction and absolute counting, being instead based on the ratios of target and non‐target populations in the original pre‐sort sample and in the waste stream or center stream catch. The Rmax method is ideal to evaluate and troubleshoot the optimum drop‐charge delay of the sorter or any instrument‐related failures that will affect sort performance. It can be used as a daily quality control check but can be particularly useful to assess instrument fitness before single‐cell or rare population sorts. Because the sorted fraction is not perturbed, we can calculate Rmax during the sort run. © 2024 The Authors. Current Protocols published by Wiley Periodicals LLC.Basic Protocol 1: Evaluating sorter setup with RmaxBasic Protocol 2: Finding the maximum Rmax: scanning over the drop charge delayAlternate Protocol: Finding the maximum Rmax for cells: scanning over the drop charge delayBasic Protocol 3: Estimating sorted cell number with Rmax

100 Deals associated with AbbVie Biotherapeutics, Inc.

Login to view more data

100 Translational Medicine associated with AbbVie Biotherapeutics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

8

Preclinical

Approved

1

4

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Ombitasvir/Paritaprevir/Ritonavir ( HIV-1 pol x NS3/NS4A x NS5A )	Chronic hepatitis C genotype 1 More	Approved
BKI-1708 ( CDPK1 )	Cryptosporidiosis More	Preclinical
TMEM-175 ( TMEM175 )	Parkinson Disease More	Preclinical
ABBV-MALT1 ( Bcl-2 x MALT1 )	Leukemia More	Preclinical
PD-1/GITR Targeted Fc Fusion protein(AbbVie) ( GITR x PD-1 )	Neoplasms More	Preclinical